Eli Lilly and Company

(New York Stock Exchange)
Back to all articles
Bullish +65

Eli Lilly Stock Rose Nearly 7% to a Record as It Lifted Its 2026 Sales Forecast to as Much as $92 Billion. Hereโ€™s Where the Stock Could Go

Drug approval Earnings report Guidance raised AI-generated analysis

๐Ÿ“ˆ Eli Lilly stock jumped nearly 7% to a record $1,373.70 after lifting its 2026 sales forecast to as much as $92 billion.

๐Ÿ’ฐ Q3 revenue surged 39% to $24.4 billion, beating consensus estimates by approximately $1.8 billion.

๐Ÿš€ The Medicare GLP-1 Bridge program and international cash-pay adoption added roughly $10 billion to the 2026 forecast unexpectedly.

โš ๏ธ Management warned that about $2 billion of 2026 revenue is non-recurring and will not repeat in future years.

๐Ÿ“‰ CFO Lucas Montarce expects net price headwinds in 2027 to offset volume growth, making the $103 billion Street estimate difficult.

๐Ÿ’Š Investigational retatrutide demonstrated superior weight loss and A1C reduction compared to Novo Nordisk's Ozempic in recent trials.

๐Ÿฅ Foundayo for type 2 diabetes is expected to receive a U.S. regulatory decision in the fourth quarter.

๐Ÿ“Š The stock trades at a premium 31x NTM P/E multiple, significantly higher than competitor Novo Nordisk's 12x multiple.

๐Ÿ”ฎ CEO David Ricks noted that as variables become predictable, future revenue guidance raises may become smaller.

๐Ÿ—“๏ธ Investors await the January earnings call for 2027 guidance to see if volume can absorb the lost one-time revenue.

Bullish Signals
  • Eli Lilly raised its 2026 revenue forecast to $91-$92 billion, a midpoint increase of roughly $10 billion over February estimates.
  • Q3 revenue grew 39% year-over-year to $24.4 billion, beating analyst consensus by approximately $1.8 billion.
  • Adjusted EPS of $7.48 exceeded the $6.35 estimate, driven by strong performance in the GLP-1 category expansion.
  • The Medicare GLP-1 Bridge program and international cash-pay adoption contributed roughly $10 billion to the 2026 forecast.
  • Investigational retatrutide showed superior clinical results with more than double the weight loss of Novo Nordisk's Ozempic.
  • Foundayo for type 2 diabetes is expected to receive a U.S. regulatory decision in the fourth quarter, adding new revenue streams.
Risk Factors
  • Approximately $2 billion of the 2026 revenue guidance consists of one-time milestones and rebate changes that management does not expect to recur.
  • CFO Lucas Montarce expects net price headwinds in 2027 to offset volume growth, making the Street's $103 billion revenue estimate challenging.
  • The stock trades at a premium valuation of roughly 31x next-year earnings compared to Novo Nordisk's 12x multiple, leaving room for compression if growth slows.
  • CEO David Ricks indicated that as the 'surprise factor' runs its course, future revenue guidance raises may become smaller and more predictable.
Full Analysis
Eli Lilly (LLY) shares surged nearly 7% to a record high of $1,373.70 after the company raised its 2026 revenue forecast to between $91 billion and $92 billion. This guidance represents a midpoint increase of approximately $10 billion compared to February estimates, driven primarily by unexpected positive outcomes in two key variables: the rapid ramp-up of the Medicare GLP-1 Bridge program and increased cash payments from middle-income households abroad for weight-loss drugs. The company reported strong third-quarter financials with revenue rising 39% year-over-year to $24.4 billion, beating analyst consensus by roughly $1.8 billion. Adjusted earnings per share of $7.48 also exceeded expectations, though GAAP EPS fell short due to significant one-time research charges totaling $4.57 per share. Management clarified that about $2 billion of the 2026 revenue guidance consists of non-recurring milestones and rebate adjustments that will not repeat in future years. Looking ahead, the company faces a challenging environment for 2027 where net price headwinds are expected to offset volume growth, potentially requiring a lower revenue multiple. CEO David Ricks highlighted that while the current expansion is the largest new category in pharmaceutical history, the 'surprise factor' will diminish as variables become more predictable. Investors are closely watching the upcoming January earnings call for 2027 guidance to determine if volume can sustain growth despite anticipated price declines and the eventual shift of the Bridge program to Medicare Part D. Analysts remain bullish on the long-term runway driven by new products like Foundayo for type 2 diabetes and investigational retatrutide, which showed superior efficacy in recent trials. However, the stock currently trades at a premium valuation of roughly 31x next-year earnings compared to Novo Nordisk's 12x multiple. The primary risk identified is the sustainability of growth if the one-time revenue boosts fade and volume fails to outpace price reductions in the coming year.